Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Outstanding (Diluted Average) (2018 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 1.78% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, up 1.78%, and an annual FY2024 reading of $4.1 million, up 666.73% over the prior year.
  • Shares Outstanding (Diluted Average) was $4.2 million for Q3 2025 at Kiora Pharmaceuticals, up from $4.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $13.1 million in Q2 2022 and bottomed at $241099.0 in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $3.4 million, with a median of $3.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 97.81% in 2023, then soared 1305.92% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $241099.0 in 2021, then soared by 108.39% to $502436.0 in 2022, then grew by 7.08% to $538007.0 in 2023, then soared by 666.73% to $4.1 million in 2024, then rose by 0.98% to $4.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KPRX at $4.2 million in Q3 2025, $4.0 million in Q2 2025, and $4.2 million in Q1 2025.